This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 45/1/69    most recent 01.HYP.0000151103.02424.c3v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Campbell, D. J. Articles by MacMahon, S. W. Search for Related Content PubMed PubMed Citation Articles by Campbell, D. J. Articles by MacMahon, S. W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Related Collections Congestive Cardiovascular Pharmacology Other diagnostic testing Other Stroke Treatment - Medical

(Hypertension. 2005;45:69.)
© 2005 American Heart Association, Inc.

Scientific Contributions

Prediction of Heart Failure by Amino Terminal-pro–B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease

Duncan J. Campbell; Mark Woodward; John P. Chalmers; Samuel A. Colman; Alicia J. Jenkins; Bruce E. Kemp; Bruce C. Neal; Anushka Patel; Stephen W. MacMahon

From the St. Vincent’s Institute of Medical Research (D.J.C., B.E.K.), Fitzroy, Victoria; the Department of Medicine (D.J.C., A.J.J., B.E.K.), University of Melbourne, St. Vincent’s Hospital, Fitzroy, Victoria; Commonwealth Scientific and Industrial Research Organization Health Sciences and Nutrition (B.E.K.), Parkville, Victoria; and The George Institute for International Health (M.W., J.P.C., S.A.C., B.C.N., A.P., S.W.M.), University of Sydney, Newtown, New South Wales, Australia.

Correspondence to Dr D.J. Campbell, St. Vincent’s Institute of Medical Research, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia. E-mail dcampbell{at}svi.edu.au

B-type natriuretic peptide (BNP) and C-reactive protein (CRP) are elevated in persons at risk for congestive heart failure (CHF). However, limited data are available directly comparing BNP-related peptides and CRP in persons at risk of CHF. To evaluate amino terminal–pro-BNP (NT-proBNP) and CRP, separately and together, for assessment of risk of CHF, we performed a nested case-control study of the 6105 participants of the Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS), a placebo-controlled study of a perindopril-based blood pressure–lowering regimen among individuals with previous stroke or transient ischemic attack (TIA). Each of 258 subjects who developed CHF resulting in death, hospitalization, or withdrawal of randomized therapy during a mean follow-up of 3.9 years was matched to 1 to 3 control subjects. NT-proBNP and CRP predicted CHF; the odds ratio for subjects in the highest compared with the lowest quarter was 4.5 (95% confidence interval, 2.7 to 7.5) for NT-proBNP and 2.9 (confidence interval, 1.9 to 4.7) for CRP, and each remained a predictor of CHF after adjustment for all other predictors. Screening for both markers provided better prognostic information than screening for either alone. Elevation of NT-proBNP above 50 pmol/L and CRP above 0.84 mg/L predicted CHF with sensitivity of 64% and specificity of 66%. NT-proBNP and CRP predicted CHF in subjects receiving perindopril-based therapy. We conclude that NT-proBNP and CRP are independent predictors of CHF risk after stroke or TIA. Moreover, NT-proBNP and CRP may be markers of mechanisms of CHF pathogenesis distinct from those responsive to angiotensin-converting enzyme inhibitor–based therapy.

Key Words: heart failure • natriuretic peptides • cerebrovascular disorders • stroke • renin

This article has been cited by other articles:

				P. O. Collinson Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death: Just Another Brick in the Wall? Clin. Chem., February 1, 2009; 55(2): 203 - 205. [Full Text] [PDF]

				A. M. Richards Natriuretic Peptides: Update on Peptide Release, Bioactivity, and Clinical Use Hypertension, July 1, 2007; 50(1): 25 - 30. [Full Text] [PDF]

				P. M. McKie, R. J. Rodeheffer, A. Cataliotti, F. L. Martin, L. H. Urban, D. W. Mahoney, S. J. Jacobsen, M. M. Redfield, and J. C. Burnett Jr Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide: Biomarkers for Mortality in a Large Community-Based Cohort Free of Heart Failure Hypertension, May 1, 2006; 47(5): 874 - 880. [Abstract] [Full Text] [PDF]

				D. J. Campbell, M. Woodward, J. P. Chalmers, S. A. Colman, A. J. Jenkins, B. E. Kemp, B. C. Neal, A. Patel, and S. W. MacMahon Soluble Vascular Cell Adhesion Molecule 1 and N-terminal Pro-B-Type Natriuretic Peptide in Predicting Ischemic Stroke in Patients With Cerebrovascular Disease Arch Neurol, January 1, 2006; 63(1): 60 - 65. [Abstract] [Full Text] [PDF]

				P. M. McKie and J. C. Burnett Jr B-Type Natriuretic Peptide as a Biomarker Beyond Heart Failure: Speculations and Opportunities Mayo Clin. Proc., August 1, 2005; 80(8): 1029 - 1036. [Abstract] [PDF]

				D. J. Campbell, M. Woodward, J. P. Chalmers, S. A. Colman, A. J. Jenkins, B. E. Kemp, B. C. Neal, A. Patel, and S. W. MacMahon Prediction of Myocardial Infarction by N-Terminal-Pro-B-Type Natriuretic Peptide, C-Reactive Protein, and Renin in Subjects With Cerebrovascular Disease Circulation, July 5, 2005; 112(1): 110 - 116. [Abstract] [Full Text] [PDF]